Similarly, the t(15;17) translocation in acute promyelocytic leukemia (APL) produces the PML::RARA fusion, rendering the disease highly responsive to differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide [51]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.